Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > seller

<< Previous

Bullboard Posts

Next >>

Comment by Blairman1on Apr 09, 2019 7:17am

72 Views

Post# 29600373

RE:seller

LMAO. Hey look, the Sky is Falling !! Wait, No , it’s Only a Short Seller named
boozehound. Hahahha. He or she comes back to the board randomly when the stock drops a little and tries to scare retail investors. What a Bully. Please it you people here have an ounce of intelligence , put him on Ignore
do your own homework and don’t waste your time

Acasti Long
The Blairman

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects